[go: up one dir, main page]

AR035913A1 - Imidazopiridinas sustituidas con fenilo, composiciones que las comprenden y uso de las mismas para la manufactura de medicamentos - Google Patents

Imidazopiridinas sustituidas con fenilo, composiciones que las comprenden y uso de las mismas para la manufactura de medicamentos

Info

Publication number
AR035913A1
AR035913A1 ARP010101555A ARP010101555A AR035913A1 AR 035913 A1 AR035913 A1 AR 035913A1 AR P010101555 A ARP010101555 A AR P010101555A AR P010101555 A ARP010101555 A AR P010101555A AR 035913 A1 AR035913 A1 AR 035913A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
alkoxy
halo
carbon
Prior art date
Application number
ARP010101555A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR035913A1 publication Critical patent/AR035913A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Imidazopiridinas sustituidas con fenilo o sales farmacéuticamente aceptables, amidas, ésteres o hidratos de las mismas que son útiles para el tratamiento y/o prevención de trastornos y condiciones mediados por el receptor H3 de histamina. Tales imidazopiridinas sustituidas con fenilo tienen la fórmula (1) en donde ambas líneas de rayas son un enlace doble carbono-carbono, o ambas están ausentes; R3 es H, alquilo C1-6 fenilo o bencilo, cada uno de R5, R6, R7 y R8 es independientemente H, alquilo C1-6, alcoxi C1-6, halo o amino; uno de Ra, Rb, Rc, Rd, y Re es -WYZ y los otros se seleccionan independientemente entre H, alquilo C1-6, alcoxi C1-6, halo y amino; W es R9, O-R9, NR10, -(CO)(O)R9, -N(R10)SO2-R9, -O(CO)R9, -(CO)R9, -(CO)NR10, o -N(R10)-CO-R9, en donde R9 es alquileno C1-6, alquinileno C2-6, alquenileno C2-6, fenileno o radical bivalente heterocíclico C2-5 y R10 es H, alquilo C1-6, alquinilo C2-6, alquenilo C2-6, fenilo o radical heterocíclico C2-5; Y está ausente, alquilo C1-6, alquinilo C2-6 alquenilo C2-6 o alcoxi C1-6; Z es radical heterocíclico C2-8 con por lo menos un átomo de nitrógeno básico en el anillo, optativamente incluyendo en el anillo hasta 3 heteroátomos adicionales o porciones independientemente seleccionadas entre O, C=O, N, NH, NG, S, SO, y SO2 en donde G es R15, COR15, COOR15, SO2R15, SO2N o CSR15; o Z es NR11R12 donde cada uno de R11 y R12 es independientemente seleccionado entre H, alquilo C1-6, fenilo, bencilo, cicloalquilo C3-8 y radical heterociclico C2-5; y R15 es alquilo C1-6, alquinilo C2-6, alquenilo C2-6, cicloalquilo C3-7, o cicloalquenilo C4-7, siempre que donde Rc es WNR11R12, cada uno de R11 y R12 se selecciona independientemente entre alquilo C1-6, entonces por lo menos uno de los siguientes es verdadero: Rb o Rd es alquilo, alcoxi, amino, o halo; las líneas de rayas representan un doble enlace carbono-carbono o están ausentes; Ra o Re es alquilo, alcoxi, amino o halo; o W es -R9-; -NR10-, (CO)(O)R9-, -O(CO)R9, -(CO)NHR9-, ó -N(R10)(CO)R9-; y además siempre que cada uno de Ra, Rb, Rd y Re es H y W es un alcoxi insustituido, de cadena recta, entonces por lo menos uno de los siguientes es verdadero: Z es cíclico; las líneas de rayas representan un doble enlace carbono-carbono o están ausentes; o R7 o R8 es alquilo, alcoxi, halo, o amino; y cada uno de los grupos hidrocarbilo o heterocíclico antes mencionado es optativamente sustituido con entre 1 y 3 sustituyentes seleccionados entre alquilo C1-3 halo, hidroxi, radical heterocíclico C2-5, fenilo y fenil(alquilo C1-3); y en donde cada uno de los grupos heterocíclicos antes mencionados puede estar adherido al resto de la molécula por un átomo de carbono o un heteroátomo. Se describen también composiciones farmacéuticas que las comprenden y uso de las imidazopiridinas sustituidas con fenilo o sales farmacéuticamente aceptables, amidas, ésteres o hidratos de las mismas para la manufactura de medicamentos.
ARP010101555A 2000-03-31 2001-03-30 Imidazopiridinas sustituidas con fenilo, composiciones que las comprenden y uso de las mismas para la manufactura de medicamentos AR035913A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19407100P 2000-03-31 2000-03-31
US27212101P 2001-02-28 2001-02-28
US09/821,244 US6908929B2 (en) 2000-03-31 2001-03-29 Phenyl-substituted imidazopyridines

Publications (1)

Publication Number Publication Date
AR035913A1 true AR035913A1 (es) 2004-07-28

Family

ID=26889666

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101555A AR035913A1 (es) 2000-03-31 2001-03-30 Imidazopiridinas sustituidas con fenilo, composiciones que las comprenden y uso de las mismas para la manufactura de medicamentos

Country Status (8)

Country Link
US (6) US6908929B2 (es)
EP (1) EP1268478B1 (es)
AR (1) AR035913A1 (es)
AT (1) ATE361297T1 (es)
AU (1) AU2001249679A1 (es)
DE (1) DE60128211T2 (es)
ES (1) ES2286114T3 (es)
WO (1) WO2001074815A2 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US6489337B1 (en) 2000-03-31 2002-12-03 Ortho-Mcneil Pharmaceutical, Inc. Method for treating histamine H3 receptor-mediated disorders with 2- or 3-aryl substituted imidazo[1,2-a] pyridines
AU2001249679A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
DE60237528D1 (de) 2001-09-14 2010-10-14 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
DE10247271A1 (de) * 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
CN1922183B (zh) * 2004-02-18 2010-05-26 万有制药株式会社 含氮的稠合杂芳环衍生物
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7504413B2 (en) * 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
US7795448B2 (en) * 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717233A1 (en) * 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
EP1717234A1 (en) * 2005-04-29 2006-11-02 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
KR101286569B1 (ko) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 신규 약제
AR056690A1 (es) * 2005-10-14 2007-10-17 Athersys Inc Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
EP1942899A4 (en) * 2005-11-02 2010-04-28 Cytokinetics Inc INHIBITORS OF MITOTIC KINESINE
RU2008150377A (ru) 2006-05-19 2010-06-27 Нихон Меди-Физикс Ко., Лтд. (Jp) Новое соединение, обладающее сродством к амилоиду
DK2079732T3 (da) 2006-05-29 2012-01-23 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazin, dets salte og solvater og dets anvendelse som histamin H3-receptorantagonister
TW200811175A (en) * 2006-06-21 2008-03-01 Nihon Mediphysics Co Ltd Novel compound with affinity with amyloid
KR20090025282A (ko) * 2006-06-21 2009-03-10 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
FR2903489B1 (fr) * 2006-07-05 2008-09-12 Airbus France Sas Procede de determination d'un chemin suivi par un flux d'une grandeur physique dans un assemblage de pieces
CN101595108A (zh) 2006-11-30 2009-12-02 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CN101636183B (zh) 2007-02-13 2014-03-19 日本医事物理股份有限公司 放射性诊断显像剂的制备方法
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
AU2008288390A1 (en) * 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
EP2062893A1 (en) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fused imidazoles for cancer treatment
CN101903381A (zh) * 2007-10-24 2010-12-01 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物
CA2704027A1 (en) * 2007-10-26 2009-04-30 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
CN101602687A (zh) * 2008-06-13 2009-12-16 上海特化医药科技有限公司 6-硝基苯乙酮类化合物、其制备方法及用途
CA2772522A1 (en) * 2009-09-11 2011-03-17 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
SI2694510T1 (sl) 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN103641827B (zh) * 2013-12-10 2015-04-29 广西师范大学 中氮茚衍生物及其合成方法和应用
CN104610255B (zh) * 2015-01-28 2017-01-18 常州工程职业技术学院 含有异噁唑骨架的[1,2‑a]咪唑并吡啶类衍生物的合成方法
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3377488T3 (da) 2015-11-19 2022-10-03 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
KR102641030B1 (ko) 2016-12-22 2024-02-29 인사이트 코포레이션 Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체
WO2018165112A1 (en) * 2017-03-09 2018-09-13 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting histone methyltransferase
FI3774791T3 (fi) 2018-03-30 2023-03-21 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
BR112020022936A2 (pt) 2018-05-11 2021-02-02 Incyte Corporation derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
MX2022003578A (es) 2019-09-30 2022-05-30 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores.
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910675B2 (ja) * 1976-03-22 1984-03-10 ウェルファイド株式会社 アラルキルアミン誘導体
US5182291A (en) 1986-02-14 1993-01-26 Sanofi Pyrozala-pyridyl aminoabkoxyphenol compounds
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US4727145A (en) 1986-09-22 1988-02-23 Ortho Pharmaceutical Corporation 2- Or 3- aryl substituted imidazo [1,2-a]pyridines
ES2026666T3 (es) 1987-03-27 1992-05-01 Synthelabo Procedimiento para preparar derivados de imidazopiridinas.
US4861897A (en) 1987-06-22 1989-08-29 Ortho Pharmaceutical Corporation 2-Aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles
US4880824A (en) 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5340828A (en) 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
US5486517A (en) 1994-05-10 1996-01-23 Warner-Lambert Company Benzimidazoles and imidazopyridines as central nervous system agents
TW593290B (en) 1996-05-10 2004-06-21 Janssen Pharmaceutica Nv Alkylaminobenzothiazole and -benzoxazole derivatives
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
HUP9603001A3 (en) 1996-10-30 1999-07-28 Richter Gedeon Vegyeszet Heterocycle compounds comprising nitrogen, process for producing them and pharmaceutical compositions containing the same
WO1998048797A1 (en) 1997-04-30 1998-11-05 Eli Lilly And Company Antithrombotic agents
WO1999032115A1 (en) 1997-12-19 1999-07-01 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
NZ505060A (en) 1997-12-24 2002-09-27 Smithkline Beecham Lab 2-Aryl or heterocyclyl substituted indole derivatives useful for the treatment of osteoporosis
EP0978512A1 (en) 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
DE19936309A1 (de) 1999-08-02 2001-02-15 Rohde & Schwarz System zum gemeinsamen Betreiben von auf verschiedene Wellenformen einstellbaren digital arbeitenden Funkgeräten
GB9927687D0 (en) * 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
AU2001249679A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines

Also Published As

Publication number Publication date
EP1268478A2 (en) 2003-01-02
DE60128211T2 (de) 2008-01-10
US20020006934A1 (en) 2002-01-17
ES2286114T3 (es) 2007-12-01
ATE361297T1 (de) 2007-05-15
US20050043348A1 (en) 2005-02-24
US20050049277A1 (en) 2005-03-03
AU2001249679A1 (en) 2001-10-15
US20050085501A1 (en) 2005-04-21
US20050085502A1 (en) 2005-04-21
US7041828B2 (en) 2006-05-09
EP1268478B1 (en) 2007-05-02
US7041827B2 (en) 2006-05-09
WO2001074815A2 (en) 2001-10-11
US7199117B2 (en) 2007-04-03
WO2001074815A3 (en) 2002-04-04
DE60128211D1 (de) 2007-06-14
US7087757B2 (en) 2006-08-08
US6908929B2 (en) 2005-06-21
US20050090523A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
AR035913A1 (es) Imidazopiridinas sustituidas con fenilo, composiciones que las comprenden y uso de las mismas para la manufactura de medicamentos
AR076076A1 (es) Compuestos biciclicos y heterociclicos fusionados,composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes
AR035260A1 (es) Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer
AR035325A1 (es) Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento
AR039124A1 (es) Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR036233A1 (es) Un compuesto derivado de indol, su uso, procesos para prepararlo y una composicion farmaceutica que lo comprende
IS2734B (is) Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
AR018915A1 (es) Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
AR072227A1 (es) Derivados de triazinona sustituidos
DE60217322D1 (de) Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
PE20090048A1 (es) Derivados de glicina n-sustituidos: inhibidores de prolil hidroxilasa
AR046845A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
PE20090694A1 (es) Compuestos moduladores de sirtuinas
TW200617002A (en) Novel substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CO5680430A2 (es) Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
CO4970807A1 (es) Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
DE60219911D1 (de) Pyrrolidin-2-on derivate als faktor xa inhibitoren
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR042733A1 (es) Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+
NO20083070L (no) Nye N-(fluor-pyrazinyl)-fenylsulfonamidler som modulatorer av kemokin-reseptor CCR4

Legal Events

Date Code Title Description
FG Grant, registration